Curated News
By: NewsRamp Editorial Staff
May 19, 2026

Quantum BioPharma Hits Midpoint in MS Imaging Study; Promising Data for Lucid-MS

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Quantum BioPharma's MS imaging study progress could accelerate Lucid-MS Phase 2, offering a potential edge over competitors.
  • The study uses [¹⁸F]3F4AP tracer PET imaging to measure demyelination, reaching halfway patient enrollment with promising data.
  • This research aims to improve MS diagnosis and treatment, potentially enhancing quality of life for millions affected.
  • A novel PET tracer directly visualizes myelin damage in MS lesions, a leap beyond traditional MRI techniques.

Impact - Why it Matters

This milestone matters because it validates a novel PET imaging technique that could revolutionize how multiple sclerosis is diagnosed and treated, potentially leading to better outcomes for millions of patients. For Quantum BioPharma, positive data strengthens the case for its lead candidate Lucid-MS and could accelerate its path to market, offering hope for those with progressive forms of MS where current therapies fall short. Investors should watch for further data readouts that could drive significant value.

Summary

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced a significant milestone in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital, reaching the halfway mark in patient enrollment. Preliminary imaging data from the study have shown encouraging signals in acute MS lesions, with potential sensitivity to gray matter lesions. The study employs a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination in the brain, a key pathological feature of multiple sclerosis. This advancement could enhance the development of MS therapies, including Quantum's investigational candidate Lucid-MS. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the FDA in March 2026, underscoring its commitment to addressing the underlying mechanisms of MS.

Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum is advancing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Additionally, Quantum has spun out its OTC product UNBUZZD(TM) to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and a royalty agreement amounting to 7% of sales until $250 million is reached, then dropping to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses. For more details, the full press release is available at https://ibn.fm/4IZ0y.

This news matters because it represents a potential breakthrough in the diagnosis and treatment of multiple sclerosis, a chronic autoimmune disease affecting millions worldwide. The ability to directly visualize demyelination with PET imaging could lead to earlier detection, more accurate monitoring of disease progression, and more effective development of therapies like Lucid-MS. For patients, this could mean improved outcomes and quality of life. For investors, Quantum's progress in clinical milestones and its strategic partnerships, including with Massachusetts General Hospital, signal a company poised for growth in the biotech sector. The advancements also highlight the broader trend of precision medicine in neurology, where targeted imaging and therapeutics are transforming patient care.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantum BioPharma Hits Midpoint in MS Imaging Study; Promising Data for Lucid-MS

blockchain registration record for this content.